Drug
LTP001
Status:
Phase 2
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Study Purpose
A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis (IPF).